Speakers

RCC   |   Lung   |   Colorectal Cancer   |   Industry

Sumanta Kumar Pal, MD

Assistant Professor, Department of Medical Oncology & Therapeutics Research

City of Hope

Sumanta Kumar Pal, M.D., is an assistant professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Kidney Cancer Program at City of Hope. Having been appointed to the faculty for just over four years, Dr. Pal has been extremely productive, publishing more than 85 manuscripts in peer-reviewed journals. He has presented his work in multiple international meetings. Dr. Pal began his college career at the age of 13 through the California State University, Los Angeles Early Entrance Program. He began medical school at the age of 17 at the University of California, Los Angeles (UCLA), where he developed an immediate interest in cancer research. Working in the laboratory of Dennis Slamon, M.D., Ph.D., Dr. Pal examined the breast cancer drug trastuzumab, performing laboratory-based studies to elucidate mechanisms of resistance to the agent. He continued this work during the course of his residency training at UCLA.
After completing his residency, Dr. Pal transitioned to City of Hope where he trained under Robert Figlin, M.D., developing clinical trials and translational studies for genitourinary cancer, principally in the domain of renal cell carcinoma and prostate cancer. He has garnered numerous awards to support his work, including grants from the California Breast Cancer Research Program, the National Comprehensive Cancer Network and the National Institutes of Health. He recently received a Young Investigator Award from the Kidney Cancer Association to recognize his outstanding research in this domain, and further received the 2012 Charles A. Coltman Translational Research Award from the Southwest Oncology Group to support his work in bladder cancer.
Dr. Pal’s vision is to take discoveries made in the laboratory and translate these findings as quickly and efficiently as possible into tangible benefits for patients.

Strategies for Minimizing Toxicities in Patients Undergoing Treatment for RCC





Jyoti Patel, MD

Associate Professor of Medicine

Northwestern University Feinberg School of Medicine

Dr Patel is Associate Professor of Medicine at the Feinberg School of Medicine of Northwestern University. She specializes in the treatment of lung cancer. In addition to developing novel therapies for lung cancer, she has a special interest in lung cancer in women and the interplay of genetic, hormonal, and molecular differences that contribute to differences in outcome in women. She graduated from Northwestern University with a degree in English Literature and received her MD from Indiana University. She then completed residency at Northwestern University, where she also served as Chief Medical Resident. She completed medical oncology fellowship at Memorial Sloan-Kettering Cancer Center. In 2003 she returned to Northwestern, and Dr Patel now serves as the Thoracic Oncology Program Leader of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. She has authored numerous publications and has served as the principal investigator of multiple clinical trials. She is Co-Chair of the Thoracic Committee of the Hoosier Oncology Group. She has is a member of the core committee of the Thoracic Committee of the Eastern Cooperative Oncology Group. She is a member of the NCCN Non-Small Cell Lung Cancer and Small Cell Lung Cancer Panels. She has served on the Scientific Program Committees of ASCO and IASLC. She was awarded the Early Career Achievement Award from Indiana University School of Medicine. She was also part of ASCO’s prestigious Leadership Development Program.

Advancing Personalized Care for Patients with NSCLC: Tumor Genotyping and Biomarkers

Advances in Targeted Therapy for NSCLC





John L. Marshall, MD

Professor and Chief, Division of Hematology/Oncology

Georgetown University Hospital









Forgot Password Click Here to Register